BUZZ-Maze Therapeutics jumps on early data for kidney disease drug
I'm PortAI, I can summarize articles.
Shares of Maze Therapeuticssurged 35% to $21.77 in premarket trading following positive early-stage trial results for its oral drug MZE782, which targets the SLC6A19 protein. The trial demonstrated significant increases in phenylalanine and glutamine excretion without serious side effects. The company plans to initiate mid-stage studies in 2026 for phenylketonuria and chronic kidney disease. Year-to-date, the stock is up 0.4%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments